A COMPARATIVE-STUDY OF ONE-YEAR WEIGHT-GAIN AMONG USERS OF MEDROXYPROGESTERONE ACETATE, LEVONORGESTREL IMPLANTS, AND ORAL-CONTRACEPTIVES

被引:65
作者
MOORE, LL
VALUCK, R
MCDOUGALL, C
FINK, W
机构
[1] PAYLESS DRUG, DENVER, CO USA
[2] UNIV COLORADO, HLTH SCI CTR, DEPT PHARM PRACTICE, DENVER, CO USA
[3] CASA GRANDE VALLEY CTR WOMEN, CASA GRANDE, AZ USA
[4] MANAGED CARE PHARM CONSULTANTS, CASA GRANDE, AZ USA
关键词
MEDROXYPROGESTERONE ACETATE; LEVONORGESTREL; ORAL CONTRACEPTIVES; ADVERSE EFFECTS; WEIGHT GAIN;
D O I
10.1016/0010-7824(95)00189-H
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
With the recent introduction and growing popularity of Depo-Provera(R) Contraceptive Injection, concern about the potential for weight gain during treatment has been raised. The purpose of the present study was to determine whether or not Depo-Provera(R) Contraceptive Injection is associated with greater weight gain, and incidence thereof, than Norplant(R) implants or oral contraceptives. A retrospective chart review of patients seen at a state- and federally-funded clinic was conducted. Fifty women in each treatment group who met the study criteria were identified and included in the study evaluation. Mean one-year weight gain for subjects in each group was as follows: -2.0 pounds in the oral contraceptive group, -1.8 pounds in the Norplant(R) implants group, and +0.1 pounds in the Depo-Provera(R) Contraceptive Injection group. While results among treatment groups differed slightly no significant weight change occurred in any of the treatment groups.
引用
收藏
页码:215 / 219
页数:5
相关论文
共 23 条
  • [11] GOLDZIEHER JW, 1971, FERTIL STERIL, V22, P609
  • [12] LONELINESS AND ADJUSTMENT TO OLD-AGE
    HANSSON, RO
    JONES, WH
    CARPENTER, BN
    REMONDET, JH
    [J]. INTERNATIONAL JOURNAL OF AGING & HUMAN DEVELOPMENT, 1987, 24 (01) : 41 - 53
  • [13] HORMONAL STEROID CONTRACEPTIVES - FURTHER REVIEW OF ADVERSE REACTIONS
    MCQUEEN, EG
    [J]. DRUGS, 1978, 16 (04) : 322 - 357
  • [14] HORMONAL STEROID CONTRACEPTIVES .4. ADVERSE REACTIONS AND MANAGEMENT OF PATIENT
    MCQUEEN, EG
    [J]. DRUGS, 1971, 2 (02) : 138 - +
  • [15] MUKHERJEA M, 1980, INT J FERTIL, V25, P122
  • [16] OPEN PROSPECTIVE MULTICENTER TRIAL WITH A NEW MONOPHASIC CONTRACEPTIVE COMBINATION CONTAINING GESTODENE
    RENIER, M
    BUYTAERT, P
    [J]. CONTRACEPTION, 1991, 43 (05) : 413 - 421
  • [17] A MULTICENTERED PHASE-III COMPARATIVE CLINICAL-TRIAL OF DEPOT-MEDROXYPROGESTERONE ACETATE GIVEN 3-MONTHLY AT DOSES OF 100MG OR 150MG .1. CONTRACEPTIVE EFFICACY AND SIDE-EFFECTS
    SAID, S
    OMAR, K
    KOETSAWANG, S
    KIRIWAT, O
    SRISATAYAPAN, Y
    KAZI, A
    AJMAL, F
    WYNTER, HH
    PRETNARDAROVEC, A
    BENITEZ, IB
    DELACRUZ, J
    APELO, R
    KOVACS, L
    KOLOSZAR, S
    BUSCA, B
    HALL, PE
    MACHIN, D
    [J]. CONTRACEPTION, 1986, 34 (03) : 223 - 235
  • [18] SCHWALLIE PC, 1973, FERTIL STERIL, V24, P331
  • [19] COMPARISON OF 2 TRIPHASIC ORAL-CONTRACEPTIVES CONTAINING EITHER GESTODENE OR NORETHINDRONE - A RANDOMIZED, CONTROLLED TRIAL
    WEBERDIEHL, F
    LEHNERT, J
    LACHNIT, U
    [J]. CONTRACEPTION, 1993, 48 (04) : 291 - 301
  • [20] CONTRACEPTIVE COMPLIANCE WITH A LEVONORGESTREL TRIPHASIC AND A NORETHINDRONE MONOPHASIC ORAL-CONTRACEPTIVE IN ADOLESCENT PATIENTS
    WOODS, ER
    GRACE, E
    HAVENS, KK
    MEROLA, JL
    EMANS, SJ
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (03) : 901 - 907